Ricerca

Pubblicazioni IRIS

• Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitors
  Anno: 2025
• CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma
  Anno: 2025
• NAD+ METABOLISM RESTRICTION BOOSTS HIGH-DOSE MELPHALAN EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA
  Anno: 2024
• Cyclic fasting bolsters cholesterol biosynthesis inhibitors' anticancer activity
  Anno: 2023
• CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents
  Anno: 2023